-
Mashup Score: 1Olomorasib Combo Elicits Favorable Efficacy in NSCLC - 20 hour(s) ago
Olomorasib with pembrolizumab in the first-line showed a 77% overall response rate in patients with KRAS G12C–mutated metastatic non–small cell lung cancer.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
A phase 2 trial shows that THIO, a new investigational drug, combined with cemiplimab, may be an effective and well-tolerated treatment for patients with advanced non–small cell lung cancer who have exhausted other options.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
THIO + cemiplimab has continued to show tolerability and lower toxicity than standard-of-care treatments in patients with advanced #NSCLC who failed 2 or more therapies, according to updated findings from the phase 2 THIO-101 study. #LCSM https://t.co/e1LDfZmH3M
-
-
Mashup Score: 1Forde Discusses AE Management With Dual Checkpoint Inhibition Plus Chemotherapy in NSCLC - 4 day(s) ago
During a Case-Based Roundtable® event, Patrick M. Forde, MD, discussed safety and tolerability concerns with immunotherapy in patients with squamous non–small cell lung cancer.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Patrick M. Forde, MD, discussed safety and tolerability concerns with immunotherapy in patients with squamous #NSCLC. #lcsm | @FordePatrick @HopkinsMedicine https://t.co/PwUxIANwwE https://t.co/OMltOelcDn
-
-
Mashup Score: 0Eftilagimod Alpha Combo Shows Promise in First-Line NSCLC - 4 day(s) ago
The phase 1 INSIGHT-003 trial showed that adding eftilagimod alpha to pembrolizumab and chemotherapy achieved a median overall survival of 32.9 months in metastatic non–small cell lung cancer.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
In the phase 1 INSIGHT-003 trial, the combination of eftilagimod alpha, pembrolizumab, and chemotherapy showed promising results in terms of overall survival & progression-free survival in metastatic nonsquamous #NSCLC. #lcsm https://t.co/JsXUjdl9IG
-
-
Mashup Score: 8Cased-Based Controversies in Locally Advanced NSCLC: A Radiation Oncology Update | IASLC - 9 day(s) ago
Dr. Stephen Chun (US) will moderate the program and lead the discussion following panel presentations by Dr. Andrea Filippi (Italy) and Dr. Pam Samson (US). As …
Source: www.iaslc.orgCategories: General Medicine News, Oncologists1Tweet-
The IASLC Advanced Radiation Technology Subcommittee of the Multidisciplinary Clinical Science Committee is hosting a webinar on radiation oncology for locally advanced #NSCLC, w/Dr. Stephen Chun, Dr. Andrea Filippi & Dr. Pam Samson. Register Now: https://t.co/jZm2qg8Lc7 #LCSM https://t.co/N1OAJ364P3
-
-
Mashup Score: 3
The use of tumor-informed circulating tumor DNA (ctDNA) testing in early-stage patients before surgery is limited mainly due to restricted tissue access and extended turnaround times. This study aimed to evaluate the clinical value of a tumor-naïve, methylation-based cell-free DNA assay in a large cohort of patients with resected non-small cell lung cancer (NSCLC).
Source: www.jto.orgCategories: General Medicine News, Oncologists1Tweet-
This study aimed to evaluate the clinical value of a tumor-naïve, methylation-based cell-free DNA assay in a large cohort of patients with resected #NSCLC. Read more about the findings here: https://t.co/o4NdaSKtHy #LCSM https://t.co/jfhRsuerCv
-
-
Mashup Score: 8Cased-Based Controversies in Locally Advanced NSCLC: A Radiation Oncology Update | IASLC - 19 day(s) ago
Dr. Stephen Chun (US) will moderate the program and lead the discussion following panel presentations by Dr. Andrea Filippi (Italy) and Dr. Pam Samson (US). As …
Source: www.iaslc.orgCategories: General Medicine News, Oncologists1Tweet-
The IASLC Advanced Radiation Technology Subcommittee of the Multidisciplinary Clinical Science Committee is hosting a webinar on radiation oncology for locally advanced #NSCLC, w/Dr. Stephen Chun, Dr. Andrea Filippi & Dr. Pam Samson. Register Now: https://t.co/jZm2qg8Lc7 #LCSM https://t.co/N1OAJ364P3
-
-
Mashup Score: 0First Patients Dosed in New Phase 3 Trials of Dato-DXd in NSCLC - 20 day(s) ago
Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
The first patients have been dosed in 3 phase 3 trials evaluating various combinations of datapotamab deruxtecan for the treatment of locally advanced or metastatic #NSCLC. #lcsm https://t.co/EIPhaptsP4
-
-
Mashup Score: 9Cased-Based Controversies in Locally Advanced NSCLC: A Radiation Oncology Update | IASLC - 26 day(s) ago
Dr. Stephen Chun (US) will moderate the program and lead the discussion following panel presentations by Dr. Andrea Filippi (Italy) and Dr. Pam Samson (US). As …
Source: www.iaslc.orgCategories: General Medicine News, Oncologists1Tweet-
The IASLC Advanced Radiation Technology Subcommittee of the Multidisciplinary Clinical Science Committee is hosting a webinar on radiation oncology for locally advanced #NSCLC, w/Dr. Stephen Chun, Dr. Andrea Filippi & Dr. Pam Samson. Register Now: https://t.co/jZm2qg8Lc7 #LCSM https://t.co/N1OAJ364P3
-
-
Mashup Score: 0
Two radiation therapy techniques, SBRT and hypofractionated CRT, may not have many differences for patients with stage 1 NSCLC, but limitations matter.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
In patients with stage 1 #NSCLC, two types of radiation therapy, SBRT or hypofractionated CRT, may not have many differences. However, limitations from the respective study matter, @BismarckOdeiMD of @UofURadOnc @huntsmancancer told CURE®. #LCSM https://t.co/y6zW8nEvTp
-
Olomorasib + pembrolizumab in the first-line showed a 77% overall response rate in patients with KRAS G12C–mutated metastatic #NSCLC. #lcsm https://t.co/d8zWBAvQzD https://t.co/gykq0TxYSU